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ABSTRACT 
Background: Fluid therapy is an important component of the treatment of septic shock. The 
Surviving Sepsis Campaign recommends early fluid resuscitation with at least 30 ml/kg and there is 
no recommendation on when to stop giving fluids. Many studies have shown an association between 
fluid overload and morbidity and mortality. Clinicians base fluid prescription on variables that do not 
reflect fluid responsiveness. 
Aim: The overall intention was to explore what scientific support there is for the treatment of septic 
patients in terms of their fluid management and the timing of antibiotics and to investigate new 
tools that could help the clinician decide on the amount and timing of blood and other fluids in 
septic shock. 
Overview of methods: 
Study Design Study Population Aim 
No of 
participants 
Statistical Methods 
I RCT 
Patients with septic shock 
and Hb ≤ 9 g/dl 
To study the effect on 
mortality of a transfusion 
threshold of 7 or 9 g/dl in 
septic shock. 
 
998 
Logistic regression, χ², 
Wilcoxon signed-rank 
test 
II Cohort 
Patients with septic shock 
and Hb ≤ 9 g/dl who 
survived and stayed in the 
ICU for three days or more 
To investigate the association 
between the cumulative fluid 
balance and mortality in 
patients with septic shock. 
 
841 
Cox regression, χ², 
ANOVA 
III Meta-analysis Critically ill patients 
To assess whether 
haemodynamic optimisation 
by protocols reduces 
mortality in critically ill 
patients. 
 
3323 
Mantel-Haenszel 
random effects model 
IV RCT (pilot) 
Patients with septic shock 
for < 12 hours 
To implement a protocol 
based on a passive leg 
raising test in patients with 
septic shock 
34 
χ², t-test, ANOVA, 
Mann-Whitney U test 
V Cohort Septic ICU patients 
To describe timing of 
antibiotics in a cohort of 
septic ICU patients 
210 
Logistic regression, t-
test, Mann-Whitney U 
test, Fisher’s exact test 
Summary of research results: The scientific support for how fluid management in patients with 
septic shock should be performed is poor.  
 It is safe to adopt a Hb threshold of 7 g/dl in septic ICU patients except in patients with pre-
existing cardiovascular disease for whom a transfusion threshold of 8 g/dl is suggested. 
 It is uncertain whether fluid overload is associated with mortality at a median fluid balance of 
2.5 l on day three.  
 It has not been proven that protocolised haemodynamic management improves outcome. 
 It was possible to use the protocol based on a passive leg raising (PLR) test, but the 
recruitment rate was low. The weight gain was low in both the PLR and the control groups. 
 Female patients and patients with surgical sepsis were overrepresented in the group that 
received antibiotics after more than one hour in the emergency department. We could neither 
confirm nor exclude a survival benefit from early administration of antibiotics. 
Keywords: septic shock, fluid therapy, randomised clinical trial, transfusion threshold, 
haemodynamic algorithms, meta-analysis, passive leg raising, transpulmonary thermodilution, 
mortality, antibiotics 
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1 INTRODUCTION 
A septic patient with low blood pressure, high pulse rate, high respiratory rate, cold and 
mottled skin and low urinary output – do they need fluids? This is an everyday clinical 
question that is difficult to answer solely on the basis of clinical examination and/or looking 
at vital parameters (1) . When working as a resident at different intensive care units in 
Stockholm, I experienced a wide local variation in the amount of fluids administered to 
patients suffering from similar diseases. A patient treated in one ICU might, after a few days, 
have gained ten kilograms due to fluid accumulation, whereas a patient with the same disease 
treated in another ICU might not have accumulated any fluid at all. I wondered whether the 
amount of fluids administered to patients had an impact on patient wellbeing and survival. 
Would it be possible to perform a test to decide whether or not a septic patient requires 
fluids? 
Fluids are administered to septic patients in order to improve their cardiac output and thereby 
oxygen delivery to their cells. However, fluids appear to have negative effects such as tissue 
oedema, impaired renal function, impaired lung function and perhaps even increased 
mortality. If it was possible to test how a patient will respond to fluid, fluid administration 
could be restricted to those patients who will benefit from this.  
This thesis is an attempt to answer a common clinical question through the application of 
quantitative scientific methodology. 
 
 
 
  3 
2 BACKGROUND 
2.1 WHAT IS SEPSIS? 
Sepsis is a syndrome in which an infection spreads and leads to a systemic inflammation. The 
pathophysiology of septic shock includes vasoplegia, endothelial dysfunction with damaged 
glycocalyx and increased leakage (2), disturbed microcirculation (3) and often myocardial 
depression (4). This sometimes leads to septic shock; sepsis with insufficient oxygen delivery 
to different organs. A patient with septic shock has low blood pressure, high pulse rate, high 
respiratory rate, either warm extremities or cold, mottled skin, impaired cerebral function 
with confusion or agitation and low urinary output. This is a dangerous state which can occur 
to anyone, independent of age or past medical history. The mortality is high (40–80%) (5) .  
At the beginning of this project, the common definition of septic shock was based on the 
systemic inflammatory response syndrome (SIRS) criteria according to a consensus 
document from 1991 (6). SIRS was present if two or more of the following criteria were 
fulfilled: 1) a body temperature > 38°C or < 36°C; 2) a heart rate > 90 beats per minute; 3) a 
respiratory rate > 20 breaths per minute 4) a white blood cell count > 12 x 10
9
/l or < 4 x 
10
9
/l. Sepsis was defined as SIRS caused by infection. Septic shock was sepsis with 
hypotension despite adequate fluid resuscitation. However, no attempt was made to define 
“adequate fluid resuscitation”. 
Over the years, the SIRS criteria have been questioned, due both to poor sensitivity (there 
are clearly septic patients in the intensive care unit who do not fulfil the SIRS criteria) and 
poor specificity (having a cold and climbing a few stairs might be enough to fulfil the 
criteria for sepsis). In a retrospective evaluation of 109 663 patients with infection and 
organ failure, 12.1% had SIRS-negative sepsis (7). Sepsis-3 was launched in 2016, as an 
attempt to link the definition of sepsis to an increased risk of mortality (8). The suggested 
new definition of sepsis is a life-threatening organ dysfunction caused by a dysregulated 
host response to an infection. Septic patients should be identified by an increase of two or 
more points in their Sequential Organ Failure Assessment (SOFA) score (9). SOFA is a 
complex scoring system that is often used in intensive care. To identify septic patients 
outside of the intensive care unit (ICU), a simple scoring system, Quick-SOFA (qSOFA), 
has been proposed: respiratory rate ≥ 22/min, systolic blood pressure ≤ 100 mmHg and 
altered mentation. A suspected infection and 2/3 criteria are required. Septic shock was 
defined as a state with serum lactate ≥ 2 mmol/l and a need for vasopressors in order to 
maintain a mean arterial pressure (MAP) > 65 mmHg. This would correspond to a hospital 
mortality > 40%.  
According to the authors, the qSOFA score needs prospective validation in other settings 
(10). The Sepsis-3 definition has not yet been generally adopted for clinical use (11). The 
SIRS criteria have been used to define sepsis in the clinical trials in this project.  
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2.2 RED BLOOD CELL TRANSFUSIONS IN SEPSIS 
Shock can be defined as a state in which oxygen delivery to the tissues is lower than their 
oxygen demand. This leads to organ dysfunction and is associated with anaerobic metabolism 
and lactate production (12). Oxygen delivery is dependent on cardiac output, haemoglobin 
concentration (Hb) and oxygen saturation of the haemoglobin molecules (SaO2). Therefore, it 
should be possible to increase oxygen delivery by transfusing blood. However, even if the 
oxygen delivery is increased, it does not always follow that the cells are able to use the extra 
available oxygen. Transfusing red blood cells (RBC) into septic patients does not necessarily 
increase oxygen consumption (13-15). One possible explanation is that there was no need for 
increased oxygen consumption in the patients examined. Another is that the poor utilisation 
of oxygen in septic patients is due to mitochondrial abnormalities rather than poor delivery. A 
small observational study of seven children suffering from hyperdynamic shock and low 
oxygen extraction showed increased oxygen consumption after RBC transfusion (16). The 
body effectively compensates for anaemia by increasing cardiac output, redistributing blood 
to vital organs, increasing capillary density, making it easier for oxygen to leave the Hb 
molecule for the tissue, and by increasing oxygen extraction (17). It has been argued that the 
lack of increase in oxygen consumption after RBC transfusion is due to changes in the 
morphology of the RBCs because of alterations that take place during storage, which impairs 
flow in the smallest capillaries. Both impaired microcirculation and increased mortality after 
transfusion of RBCs that have been stored > 31 days have been shown (18). It is not known 
to what extent RBC transfusion increases oxygen consumption in septic patients who are not 
bleeding. It is common in intensive care for the physician to set physiological goals for each 
patient in the morning. The nurses then work to achieve these goals. If they are unable to 
reach the goal, the physician is notified. The traditional goal has been Hb > 10 g/dl, but in a 
recent study the median transfusion trigger was 8.3 g/dl (19). The most common negative 
effect of RBC transfusions is transfusion-associated circulatory overload (TACO) (1:18–
1:356 events to number of transfusions) which is defined as pulmonary oedema due to 
volume overload (20, 21). Incompatibility reactions that occur when the wrong blood type is 
administered to a patient are uncommon (1:14 000-1:38 000). Other negative effects are 
haemolytic transfusion reactions (1:9 000) and infections (bacterial contamination 1:14 000, 
hepatitis C 1:1 935 000) (22). Various populations have been studied in order to determine 
when the possible beneficial effects outweigh the risks of negative effects. A large 
randomised controlled trial (RCT) of critically ill patients showed no significant difference in 
mortality between transfusion triggers of 7 g/dl or 10 g/dl, but in individuals with less severe 
illness, lower mortality was observed in the lower threshold group (23). The blood was not 
leukocyte-depleted, which might have resulted in more immunologic reactions. It has thus 
been uncertain what the optimal Hb threshold is in patients with septic shock. 
2.3 WHY ADMINISTER FLUIDS IN SEPSIS? 
2.3.1  Fluid responsiveness 
The reason for administering fluids to septic patients is to improve cardiac output and thereby 
oxygen delivery. In clinical practice, however, cardiac output is not often measured. 
Consequently, fluids are usually administered in response to low blood pressure and high 
pulse rate. Preload is the stretching of the muscle cells in the left ventricle at the end of 
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diastole and is dependent on the volume of blood returning to the heart. The heart tries to 
pump out all returning blood, which means that if fluids are given, stroke volume (SV) will 
increase as long as the heart can increase its capacity, in accordance with Starling’s law (24) . 
The relationship between preload and stroke volume is illustrated in a Frank-Starling curve 
(Fig. 1A). As both ventricles work on the steep part of the Frank-Starling curve, the heart is 
preload-dependent. A fluid responder is defined as a subject who manages to increase SV at 
increased preload, for example by 10% after 500 ml of fluid (Fig. 1B). If too much fluid is 
given or if the heart is failing, there will be no increase in cardiac output (Fig. 1 C). Only 50% 
of critically ill patients are fluid responsive (25).  
  
2.3.2  Preload is not always increased by fluid administration  
The driving pressure for venous return is the right atrial pressure (RAP) subtracted from the 
mean circulatory filling pressure (MCFP). MCFP is the pressure that can be measured when 
the heart is stopped and the arterial and venous pressures are equalised. This was conducted 
experimentally in dogs by Guyton et al. (26). MCFP describes the relationship between fluid 
volume, vascular tone and external vascular pressure. It is a measure of the elastic recoil 
potential in the entire circulatory system, including the heart and lungs. Venous return is also 
dependent on the dimensions of the vessels (which are important for the venous resistance) 
and the viscosity of the blood (27).  
Fig. 1. The Frank-Starling curve.  
A. The basis of haemodynamic 
optimisation: increased preload leads to 
increased stroke volume. 
B. A fluid responder is defined as a 
person who manages to increase SV at 
increased preload, for example by 10% 
after 500 ml of fluid. If enough fluids 
are administered and preload is 
increased, all people will reach a point 
at which more fluids do not increase 
SV (non-responder).  
C. A patient with a failing heart does 
not manage to increase SV, even at a 
low level of preload.  
Reprinted from Monitoring fluid 
responsiveness, Hofer
 
CK, Canneson 
M, Acta Anaesth Taiw, Vol 49; 2, 
2011, 59–65, with kind permission 
from Elsevier. 
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The function of venous return and cardiac function can be illustrated in the same diagram 
(Fig. 2) (28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Factors regulating CO according to Guyton. 
The RAP (here Pra) and CO are both dependent on cardiac contractility and venous return. Q = blood flow. 
The driving pressure for venous return is (MCFP - RAP). Venous return is also dependent on the dimensions 
of the vessels and the viscosity of the blood. If there is no flow, RAP equals MCFP.  
Reproduced from Magder S, (2012) Bench-to-bedside review: An approach to hemodynamic monitoring--
Guyton at the bedside. Crit Care 16: 236, with kind permission from Crit Care/ BioMed Central in accordance 
with the open access agreement. 
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Unstressed blood volume is the blood in the veins that does not contribute to venous return. It 
is the blood volume when the transmural pressure is zero. The amount of blood that has to be 
removed to reduce the transmural pressure to zero is the stressed blood volume. This 
definition is of clinical importance because hormones and drugs can change venous return by 
shifting the relationship between stressed and unstressed blood volumes (Fig. 3) (29).  
 
 
 
 
 
 
 
A fluid bolus that is accommodated as unstressed volume does not increase CVP and does 
not challenge the heart to increase the SV. Epinephrine increases CO mainly by constricting 
the capacitance vessels in the splanchnic circulation, which leads to an increase in the 
stressed blood volume. 
Fig. 3. The relationship between stressed and unstressed blood volume. 
A. The dark fluid is the unstressed volume.  
B. In sepsis the vasodilatation reduces the stressed volume and the venous return. The venous 
return can be restored by vasoconstriction or fluid administration.  
Reproduced from Miller A, Mandeville J, (2016) Predicting and measuring fluid responsiveness 
with echocardiography. Echo research and practice 3: G1-g12, with kind permission from the 
author in accordance with the open access agreement. 
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In conclusion, fluids are administered to increase CO. The heart may not respond in this way 
as fluids can be trapped as unstressed volume or leak out of the vessels or because the patient 
may not be able to respond to fluids due to a failing heart. In addition, the duration of 
increased SV after fluid bolus is short and returns to baseline within an hour following the 
administration of a fluid bolus (30). 
 
2.4  SIDE EFFECTS OF FLUIDS 
Fluid therapy is an important component of the treatment of septic shock. However, fluids do 
have negative effects. Fluids leak from the vessels and cause oedema in all tissues. Several 
studies have shown an association between fluid balance and mortality in patients in septic 
shock (31-34). However, it is uncertain whether the increased mortality is due to a higher 
fluid balance or if an increased need for fluids is simply a marker of illness severity. Even 
though all studies are adjusted for severity of illness in some way, there is still the possibility 
of residual confounding. There is one trial in which fluid boluses of 20–60 ml/kg or no 
boluses were given to Ugandan, Kenyan and Tanzanian children with septic shock; this 
showed that second day mortality was 10.6% in the albumin bolus group and 7.3% in the 
control group (35). The children were treated in paediatric wards and the results may not be 
generalisable to a setting where respiratory support is available. Nevertheless, it is a result 
that raises doubts about the beneficial effect of fluids.  
Given that one clinical argument for giving fluids is to maintain renal perfusion and thus 
renal function, it may be surprising that a high fluid balance is associated with impaired renal 
function (36, 37). One reason why the kidney is more sensitive to fluid overload than other 
organs may be that it is encapsulated and therefore has a limited ability to accommodate 
volume changes (38). A regimen with more resuscitation fluids may lead to more problems 
with abdominal hypertension and abdominal compartment syndrome (39). It has long been 
known that fluid overload impairs weaning from mechanical ventilation (40, 41) . Fluid 
overload is also associated with lower levels of mobilisation following discharge from ICU 
(42).  
2.5 FLUID ADMINISTRATION IN SEPSIS TODAY 
Fluids, norepinephrine, dobutamine and RBC transfusion were the essence of the landmark 
trial of early goal-directed therapy (EGDT) by Rivers and colleagues. The EGDT protocol is 
described in detail in Fig. 4. The authors found a hospital mortality of 46.5% in the standard 
  9 
care group and 30.5% in the EGDT group (43). 
 
 
 
 
 
 
 
 
It was a single-centre trial, and it has been criticised for lacking generalisability as the 
patients were severely ill when they arrived in the ER. This trial was the basis for sepsis 
guidelines for nearly 15 years. The trial was reproduced in three large trials, which found no 
difference in mortality between the EGDT groups the control groups (44-46). The 
recommendation from the Surviving Sepsis Campaign (SSC) is to initiate early fluid 
resuscitation with at least 30 ml/kg, and then more until the goals of CVP 8–12 mmHg, 
central venous oxygenation (ScvO2) ≥ 70%, mean arterial pressure (MAP) ≥ 65 mmHg and 
urinary output ≥ 0.5 ml/kg are achieved (47). One problem with this recommendation is the 
lack of an indication of how long it is to be followed. The EGDT protocol was used during 
Fig 4.  Protocol of early goal-directed therapy. The goals were CVP 8–12 mmHg, 
central venous oxygenation (ScvO2) ≥ 70%, MAP ≥ 65 mmHg and urinary 
ouput ≥ 0.5 ml/kg. 500 ml of fluids were administered every 30 min until the 
goal of CVP was fulfilled. Norepinehrine was administered if MAP was < 65 
mmHg. RBC were administered if ScvO2 < 70% and haematocrite < 30%. If 
ScvO2 was < 70% and haematocrite > 30%, dobutamine was administered to 
increase CO.   
 
Reproduced with permission from Rivers E, Nguyen B, Havstad S, Ressler J, 
Muzzin A, Knoblich B, Peterson E, Tomlanovich M, (2001) Early goal-
directed therapy in the treatment of severe sepsis and septic shock. N Engl J 
Med 345: 1368-1377, Copyright Massachusetts Medical Society 
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the initial six hours. In clinical practice, however, the recommendation can be used over the 
course of several days. This practice has led to huge resuscitation volumes. In the 
Vasopressin and Septic Shock Trial (VASST), in which either vasopressin or norepinephrine 
were given to patients with septic shock between 2001 and 2006, the mean cumulative fluid 
balance after four-days’ volume was 11 +/- 8.9 l (31, 48). Another objection is that CVP does 
not predict fluid responsiveness (49). The published association between fluid balance and 
mortality has probably led to the ICU community reducing the amount of resuscitation fluids. 
For example, the amount of fluids given during the first 72 hours in the three recent EGDT 
trials were significantly lower than those in Rivers and colleagues’ trial (50) .  
 
2.6 CAN THE NEED FOR FLUIDS BE EVALUATED PRIOR TO FLUID 
ADMINISTRATION? 
2.6.1 Evaluation of need for fluids using standard clinical signs 
The fluid bolus strategies used in ICUs were recently investigated in a global cohort study 
(51). The main reason for fluid administration were hypotension (59%), oliguria (18%) and 
weaning from vasopressors (7.1%). Astonishingly, the result of the first bolus did not impact 
the prescription of the next bolus. In a French study, the median volume of fluid boluses 
during 96 hours of shock was 1.5 l (IQR 1.0 - 3.0) (52). Advanced haemodynamic monitoring 
to guide the fluid bolus was only used in 23.6% of the fluid bolus situations. The main 
reasons for fluid administration were hypotension (79%), oliguria (49%), high pulse rate 
(29%), skin mottling (25%) and high lactate (19%). There seems to be a discrepancy between 
the rationale behind administering fluids to patients who are fluid responsive and clinical 
practice. It is difficult to predict fluid responsiveness from standard haemodynamic 
parameters such as heart rate, blood pressure and urinary output (1). The adequacy of 
physicians’ estimations of CO was assessed by Perel et al. They compared expected values 
with measured values of cardiac output in patients who were soon to be monitored by 
transpulmonary thermodilution (TPTD). The Bland-Altman plot between expected and 
measured CO values showed a bias of -1.54 l/min and the limits of agreement were -5.8 to 
2.6 l/min. The physicians tended to underestimate high values and overestimate low values 
(53). 
2.6.2 Passive leg raising test 
Dynamic parameters that test the position on the Frank-Starling curve through an 
increase/decrease in venous return can predict fluid responsiveness. Pulse pressure variation 
(PPV) and stroke volume variation (SVV) are examples of dynamic parameters that utilise 
the reduced preload and increased afterload for the right ventricle during mechanical 
inspiration. However, using them to reliably predict fluid responsiveness requires a regular 
heart rate and mechanical ventilation with a tidal volume  ≥ 8 ml/kg (54, 55). It is rare that 
these requirements are met in critically ill patients (56). Passive leg raising (PLR) is a test that 
can predict fluid responsiveness with 85% sensitivity and 91% specificity if the PLR test is 
evaluated using continuous cardiac output monitoring. This is independent of regular rhythm 
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and mechanical ventilation. The ideal cut-off for fluid responsiveness is an increase in CO by 
≥ 10% +/- 2% (57). It is preferably performed with an initial head-of-bed (HoB) elevation of 
45
◦
 in order to increase the amount of blood in the legs. The HoB elevation is then decreased 
as the legs are raised to 45
◦
. If CI then increases by 7–15%, the patient is considered fluid 
responsive (Fig. 5). 
 
So far, the PLR test has been implemented in two clinical trials. Richard et al. performed an 
RCT comparing the effect of a PLR test on time to weaning from vasopressors with that of a 
CVP-guided algorithm in patients with septic shock (56). There was no statistically 
significant difference between the groups. The PLR group received significantly less daily 
fluids. Kuan et al. performed a trial lasting up to three hours in septic patients in the ER in 
which patients were randomised to receive either fluid boluses given until SVI increased by < 
10% in a PLR test or standard care. There was no statistically significant difference in the 
percentage that reached a 20% lactate reduction in three hours in these groups (58). There 
was a pilot study performed by Chen et al. in which a PLR test was used to guide either fluid 
loading or targeted fluid minimisation through reduced input and increased output by 
diuretics/CVVHD, depending on the response (59). They used three parameters to determine 
fluid responsiveness: a decrease in PPV to < 13%, an increase in SVI difference by > 10% or 
decreased inferior vena cava (IVC) distension index to < 18%. Patients fulfilling two criteria 
were considered fluid responsive. It is unclear if a PLR test can be used to improve the 
outcome of septic patients. 
 
Fig. 5. The performance of the PLR test. 
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2.7 THE IMPACT OF TIMING OF ANTIBIOTICS ON MORTALITY IN SEPSIS 
 
A landmark retrospective study of the effect on mortality of delaying adequate antibiotic 
administration from the onset of hypotension in sepsis was published 2006 by Kumar et al. 
(60). The OR for hospital mortality was 1.12 (CI 1.103–1.136) for every hour of delay in the 
administration of adequate antibiotics. The average decrease in survival was 7.6% for every 
hour of delay. There was a linear relationship between the delay in the administration of 
adequate antibiotics in septic shock and mortality. Ever since the publication of this article, it 
has been stressed that early administration of antibiotics is of the highest priority in sepsis. 
The SSC recommends administering broad spectrum antibiotics within one hour of the 
recognition of severe sepsis and septic shock. The level of evidence according to the GRADE 
system (61) for this recommendation was estimated by the SSC to be 1B for septic shock and 
1C for severe sepsis (47). A prospective cohort study of patients in the ER failed to confirm 
an increase in hospital mortality per hour of the delay in administering antibiotics. The 
overall mortality in that study was much lower than in the study by Kumar et al. and most 
patients received antibiotics within three hours of being triaged in the ER (62). Patients with 
sepsis need antibiotics, but determining who has sepsis and who has other life-threatening 
disorders is not always easy. Prescribing broad spectrum antibiotics to all haemodynamically 
unstable patients might lead to the unnecessary prescription of antibiotics, with a risk of 
increased antibiotic resistance.  
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3 AIMS OF THE THESIS 
The overall intention was to explore what scientific support there is for the treatment of 
septic patients in terms of their fluid management and the timing of antibiotics and to 
investigate new tools that could help the clinician decide on the amount and timing of blood 
transfusion and fluid administration in septic shock. The specific aims were:  
 
1. To evaluate the effects on mortality of blood transfusion at a lower versus a higher 
haemoglobin threshold among patients with septic shock. 
 
 
2. To investigate the association between a cumulative fluid balance three days after 
randomisation in the intensive care unit (ICU) and 90-day mortality in patients with 
septic shock. 
 
 
3. To assess whether haemodynamic optimisation using protocols based on 
haemodynamic monitoring reduces mortality in critically ill patients. 
 
 
4. To implement passive leg raising as a new method of evaluating fluid responsiveness 
in patients with septic shock in the intensive care unit. 
 
5. To describe the timing of antibiotics in a cohort of septic ICU patients. 
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4 ETHICAL CONSIDERATIONS 
The involvement of humans in research projects requires considerable reflection. Two key 
questions have been: “Would I like my mother to participate in this research project?” and 
“Are the risks of participation outweighed by the possible gain from the trial?” 
In the TRISS trial, some clinicians found it hard not to transfuse patients with, for example, 
known ischemic heart disease until their Hb was ≤ 7 g/dl. The trial was justified, however, as 
there is equipoise between harm and benefit for RBC transfusion at this Hb threshold. There 
were safety measures that ensured patients would receive RBCs in the event of current 
myocardial ischemia or bleeding. 
In the PLR trial we chose to study severely ill patients (patients in septic shock) in order to 
include only those patients who would benefit from advanced haemodynamic monitoring. 
Being critically ill and subject to critical care is dangerous. Blood pressure monitoring via an 
arterial line is part of routine intensive care. Arterial cannulation carries a small, but not 
negligible risk of bleeding and occlusion of the involved artery. There is a risk of 
haematomas at removal of the catheter of 6.1%, bleeding of 1.6% and of serious ischemic 
events due to occlusion of 0.2% (63). Advanced haemodynamic monitoring with TPTD 
requires a femoral or axillary arterial line instead of a radial arterial line. We judged that the 
extra risk of randomising patients to advanced haemodynamic monitoring was acceptable. 
Critically ill patients are more vulnerable than healthier patients. They depend heavily on the 
care provided and there is a risk of patients or relatives agreeing to participate because they 
erroneously believe they will receive better care. To avoid this, all patients and relatives 
received both written and oral information, informing them that their future care would not 
depend upon their participation in the trial. They also received information that they could 
withdraw from the trial at any time without explanation. 
The Helsinki Declaration states that groups that are underrepresented in medical research 
should be provided appropriate access to participation in research. Swedish legislation makes 
it difficult to perform intensive care trials as delayed consent is not allowed and research 
involving drugs on unconscious patients is not allowed. Thus there is a risk that the 
vulnerable critically ill patients are excluded from the benefits of research. 
Ethical approval has been obtained for the TRISS trial (Denmark H-3-2011-114, Finland 
NTO 1/2013, Sweden EPN 2011/1603-31/2 and Norway 2011/2270/REK Vest) and for the 
TRISS-Fluid Balance study (Sweden EPN 2015-168-32/2 and Norway 2011/2270/REK 
Vest). In Denmark and Finland, the post-hoc analysis did not require an amendment. The 
ethical approval for the PLR trial was EPN 2013/1337-31/2. The ethical approvals for study 
V were EPN 2010/1780- 31- 2 and EPN 2011/1915-32/2. 
The clinical trials were registered at ClinicalTrials.gov (TRISS NCT01485315, PLR NCT 
02301585). The meta-analysis was registered at PROSPERO (2015:CRD42015019539). 
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The clinical trials have been performed in accordance with the WMA Declaration of Helsinki 
(64).  
 
5 METHODS 
5.1 OVERVIEW OF METHODS  
The studies were performed using quantitative methods. An overview of the study methods is 
presented in Table 1. Study I was a large multi-centre trial, my contribution to which was 
being responsible for the trial at Södersjukhuset. Study II was a cohort study; a post-hoc 
analysis of Study I. Study III was a systematic review and meta-analysis. Study IV was a 
single-centre clinical trial that ended as a pilot study. Study V was an observational cohort 
study. 
Study Design Study Population Aim 
No of 
participants 
Statistical Methods 
I RCT 
Patients with septic shock 
and Hb ≤ 9 g/dl 
To study the effect on 
mortality of a transfusion 
threshold of 7 or 9 g/dl in 
septic shock. 
 
998 
Logistic regression, χ², 
Wilcoxon signed-rank 
test 
II Cohort 
Patients with septic shock 
and Hb ≤ 9 g/dl who 
survived and stayed in the 
ICU for three days or more 
To investigate the association 
between the cumulative fluid 
balance and mortality in 
patients with septic shock. 
 
841 
Cox regression, χ², 
ANOVA 
III Meta-analysis Critically ill patients 
To assess whether 
haemodynamic optimisation 
by protocols reduces 
mortality in critically ill 
patients. 
 
3323 
Mantel-Haenszel 
random effects model 
IV RCT (pilot) 
Patients with septic shock 
for < 12 hours 
To implement a protocol 
based on a passive leg 
raising test in patients with 
septic shock 
34 
χ², t-test, ANOVA, 
Mann-Whitney U test 
V Cohort Septic ICU patients 
To describe timing of 
antibiotics in a cohort of 
septic ICU patients 
210 
Logistic regression, t-
test, Mann-Whitney U 
test, Fisher’s exact test 
 
Table 1. Overview of study methods. 
5.2 STUDY DESCRIPTIONS 
Study I was a large international multi-centre RCT. Patients with septic shock and Hb ≤ 9 
g/dl were randomised to a transfusion trigger of either 7 g/dl or 9 g/dl during their entire ICU 
stay or up to a maximum of 90 days. Exclusion criteria were life-threatening bleeding, acute 
coronary syndrome, acute burn injury, having already received RBC in the ICU, previous 
reactions to RBC transfusion, refusal to receive RBC transfusion, withdrawal from active 
treatment and lack of consent. The median age was 67 years and the median SAPS II was 
51(IQR 42 - 62) in the lower threshold group and 52(IQR 44 - 64) in the higher threshold 
group. The main sources of sepsis were the lungs and the abdomen. The trial was performed 
in 32 ICUs in Denmark, Norway, Finland and Sweden from Dec 2011 to Dec 2013. See Fig. 
6 for patient flow. 
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Study II was a cohort study, a secondary analysis of the TRISS trial. Patients who had been 
included in the TRISS trial, stayed in the ICU for ≥ 3 days, had complete fluid balance data 
and had given consent for use of the full dataset were grouped according to their fluid balance 
at the end of day 3. The study was performed from Jan 2014 to Oct 2015. 
Study III was a meta-analysis. We evaluated the effect of structured haemodynamic 
protocols based on CO, SV, SVV, oxygen delivery, mixed venous oxygenation (SvO2) and 
ScvO2 on mortality in adult critically ill patients. We defined the meta-analysis by the 
Cochrane acronym PICO (participants, interventions, comparators, and outcomes). 
Participants were adult patients treated at an ICU, emergency department or corresponding 
level of care. The intervention had to be protocolised and based on results from 
haemodynamic measurements, defined CO, SV, SVV, oxygen delivery, ScvO2 or SvO2. 
Comparators: The control group had to be treated using the standard care, without any 
structured intervention based on the parameters mentioned above. Algorithms based only on 
CVP for evaluating fluid requirements were regarded as inefficient and control groups treated 
Fig. 6. Patient flow in the TRISS trial.  
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in accordance with such were accepted. The selection of studies is described in a PRISMA 
flow diagram (Fig. 7). The study was performed from Dec 2014 to Jan 2016. 
 
 
 
 
Study IV was a pilot RCT. Adult patients with septic shock admitted to the ICU were 
randomised to a PLR test before every decision on resuscitation fluids or usual care. 
Exclusion criteria were >12 hours since the onset of septic shock, a contraindication to a 
femoral or axillary arterial line, a fracture of the hip or other pathology that would render the 
PLR test painful, femoral amputation, the clinical suspicion of elevated intra-abdominal 
pressure, an elevated intracranial pressure or imminent death (within 24 hours). The mean age 
was 71 +/- 11 in the PLR group and 67 +/- 15 in the control group. The primary source of 
infection was the abdomen (47.0%). The trial was performed in the surgical ICU at 
Södersjukhuset from Feb 2014 to Jan 2016. The patient flow in the PLR trial is described in 
Fig. 8. 
Fig. 7. PRISMA 2009 flow diagram for the meta-analysis. 
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Fig. 8. CONSORT flow diagram for patient flow in the PLR trial. 
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Study V was an observational cohort study performed in four ICUs in Stockholm involving 
patients admitted to the ICU in the period 2005–2010. Patients who had been diagnosed with 
sepsis and stayed ≥ 4 days in the ICU, had been diagnosed with sepsis on arrival in the ER 
and had a known time for the first administration of antibiotics were included in the study 
(Fig. 9).  
627 patients diagnosed with sepsis in the ICU
299 patients with sepsis on 
admission to hospital
328 patients who 
developed sepsis in 
hospital (excluded)
210 patients included in the 
analysis
89 patients without
documented time of 
antibiotic administration 
(excluded) 
 
 
 
5.3 MEASUREMENTS AND DATA COLLECTION 
 
In Study I, we measured Hb using a point-of-care blood gas machine (ABL 625, 700- and 
800-series or ABL90 from Radiometer, Copenhagen, Denmark [31 ICUs] or Cobas b 221 
from Roche Diagnostics, Rotkreuz, Switzerland [one ICU]). If an assigned transfusion level 
was reached, the patients received single units of cross matched, prestorage leukoreduced 
RBCs suspended in a saline-adenine-glucose-mannitol solution. Hb was then measured 
within three hours of the completed transfusion and additional RBCs were administered if 
required by the protocol. The clinical staff recorded the Hb and information about the 
transfused RBCs on paper. The researchers entered data concerning underlying diseases, 
laboratory values, fluid therapy, etc. into the online case report form (CRF). Ninety day 
mortality was gathered from patient files or regional and national registries. 
 
In Study II we divided the population into four groups according to weight-adjusted 
cumulative fluid balance. The weight was the actual or estimated body weight used for 
dosing drugs. We had a priori decided on the groups: < 0 ml/kg, 0–29.9 ml/kg, 30–75 
Fig. 9. Patient flow, Study V. 
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ml/kg and > 75 ml/kg. We chose < 0 ml/kg as we expected a negative fluid balance to be an 
advantage. Thirty ml/kg was a cut-off as this was the expected median based on data from 
Study I. An increased fluid balance of > 10% has previously been associated with increased 
mortality (37), hence the cut-off of > 75 ml/kg. 
 
A team of five researchers gathered the data for Study III in accordance with the Cochrane 
Handbook for Systematic Reviews of Interventions (65). We searched the PubMed, Embase 
and CENTRAL databases for articles using the following search terms: [(“intensive care” OR 
“intensive care units” OR “ICU” OR critically ill OR critical illness OR emergency service 
OR emergency department) AND (cardiovascular agents OR fluid therapy) AND mortality]. 
The search was performed on 18 December 2014 with an updated search on 4 January 2016. 
Titles and abstracts were screened by two researchers. If there were differences of opinion, 
two more reviewers examined the article and consensus was reached after a joint discussion 
in the team. The articles included were read by a minimum of two researchers and data was 
collected using a data collection form customised from the standardised Cochrane 
Collaborative form. The risk of bias (ROB) in each trial was assessed by two researchers. As 
it is impossible to perform a blinded trial concerning haemodynamic management, we 
deviated from the recommendations in the Cochrane Handbook and our pre-planned analysis 
registered at PROSPERO (2015:CRD42015019539). Trials with a high ROB in the domain 
of blinding of participants and personnel and a low ROB in all other domains were regarded 
as having a low ROB. Otherwise the meta-analysis would not have contained any trials.  
In Study IV, the patients in the PLR group received either a femoral or an axillary arterial 
line. The insertion was guided by ultrasound. They were monitored with PiCCO
®
 (Pulsion 
medical systems, Feldkirchen, Germany) which gives a continuous CO by pulse contour 
analysis calibrated by TPTD (Fig. 10). Calibration with thermodilution was performed three 
times per day, or more if there were large fluctuations in the dose of norepinephrine. 
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A PLR test was performed before every decision on resuscitation fluid administration, Fig. 
11. 
Algorithm for the PLR group
To be used before every decision to give fluids(except
nutrition)
≥10% 
increase
in SVI
PLR 
test
Good response to 
fluids. The physician
prescribes a desired
amount of fluids. New 
PLR test before next
decision on fluids.
<10% 
increase
in SVI 
Goals
SVI  ≥35 ml/m²
MAP ≥65 mmHg
If SVI low and the patient has 
AF>130/min in spite of fluids 
administered, consider
amiodarone
If SVI<35 consider
levosimendan
 
 
Fig. 10. Schematic view of the PiCCO monitoring device. 
Reproduced with permission from Pulsion, Feldkirchen, Germany. 
 
Fig 11. Haemodynamic algorithm for the PLR group. 
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We measured weight in the ICU bed (TotalCare SpO2RT
®
, Hill-Rom, Chicago, IL, USA) in 
the morning according to a standardised ward protocol. The accuracy of the bed scale was 
compliant with the EN45501 class 4, with a maximum permissible error of +/- 0.5 kg. If a 
patient was discharged from the ICU before the full three days, the ICU bed that had been 
used by the patient was transported to the ward and the patient was weighed by the 
researchers. The clinical staff screened and included patients in an electronic case report form 
(eCRF) that was linked to the electronic medical records. They also entered the 
haemodynamic variables from the PLR test. The researchers entered additional information 
concerning laboratory values and underlying diseases into the eCRF. 
In Study V, we screened patients for inclusion if there was a diagnosis of sepsis in the 
electronic monitoring system (Clinisoft®, General Electric, Barrington, IL, USA). 
We gathered information about time of arrival to the hospital, time of first administration of 
antibiotics, comorbidities, etc. from the medical records. We used Statistics Sweden’s Total 
Population Register to gather data on 90-day mortality. 
 
 
5.4 STATISTICAL METHODS 
In Study I, a statistician who was blinded to the allocation of the patients performed logistic 
regression on the modified intention to treat population (7 patients were deleted after 
randomisation; 6 due to withdrawal of consent and one because inclusion criteria were not 
met) with adjustment for the stratification variables (haematological cancer and study site). 
Odds ratios (OR) were converted to relative risks (RR). The RR were calculated for the pre-
specified subgroups (chronic cardiovascular disease, age > 70 years and SAPS II > 53) with 
adjustment for the stratification variables .We analysed binary outcomes with the χ² test and 
ordinal data and rate with the Wilcoxon signed-rank test.  
In Study II, we performed univariable Cox regression analysis with predefined covariates 
(age, sex, presence of haematological malignancy, site [sites with < 10 patients were 
grouped together], allocated Hb threshold, chronic cardiovascular or lung disease, source of 
infection, baseline SOFA score, highest plasma lactate in the 24 hrs before randomisation 
and acute/chronic RRT before randomisation). Variables with p < 0.1 were included in the 
final multivariable Cox regression model. The same variables were used to analyse the 
secondary outcomes. We compared categorical variables with the χ² test and continuous 
variables with the one-way ANOVA.  
 
In Study III, we used the χ² statistics to assess statistical heterogeneity of treatment effect, 
where a p-value < 0.10 was interpreted as evidence of heterogeneity. We also used the I
2
 
statistics to assess the impact of statistical heterogeneity on the treatment effect. An I
2 
of 0–
40% was interpreted as indicating that the inconsistency might not be important. We chose 
the Mantel-Haenszel random effect model because the criteria for the fixed effect model 
were not fulfilled (same direction and size of effect in all studies). We had large clinical 
heterogeneity, which was another reason for choosing the random effects model. Effects 
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were presented as OR with a 95% confidence interval. We also performed a trial sequential 
analysis (TSA) to calculate the requested meta-analysis information size (IS)(66). 
 
In Study IV, we analysed continuous normally distributed data with the independent 
samples t-test or ANOVA. We analysed continuous data with skewed distribution with the 
Mann-Whitney U test and categorical data with the χ² test. We performed intention-to-treat 
analyses. 
 
In Study V, we estimated the association between late administration of antibiotics and 90-
day mortality using multivariable logistic regression, adjusting for SAPS-3 score, gender and 
surgical sepsis. We analysed continuous normally distributed data with the independent 
samples t-test and continuous data with skewed distribution with the Mann-Whitney U test. 
We used Fisher’s exact test for categorical data. 
 
In Study I, we used SAS software, version 9.3 (SAS Software, SAS Institute Inc., Cary, NC, 
USA), and IBM SPSS Statistics software, version 17.0 (IBM Corp., Armonk, NY, USA) for 
statistical analyses. In Studies II–V, we used IBM SPSS Statistics software version 21 and 
22 (IBM Corp., Armonk, NY, USA). 
 
In all tests, p < 0.05 was regarded as statistically significant. 
6 RESULTS, COMMENTS AND METHODOLOGICAL 
CONSIDERATIONS 
The most important findings of the studies are presented here. For all results, please refer to 
the articles and manuscripts with appendices enclosed at the end of this book. 
6.1 THE EFFECT OF TRANSFUSION THRESHOLDS ON MORTALITY 
In Study I, the 90-day mortality was 43.0% in the low threshold group and 45.0% in the high 
threshold group, RR 0.94 (CI 0.78–1.09), p = 0.44. A lower Hb threshold led to fewer RBC 
transfusions; in the lower threshold group 1545 transfusions were performed, compared with 
3088 in the high threshold group. There was no difference in the percentage of ischemic 
complications; 7.2% in the lower threshold group suffered from at least one ischaemic event, 
compared with 8.0% in the higher threshold group. It is important to note that it was more 
common to transfuse a patient who was above the Hb threshold in the low threshold group; 
10% of patients in the low threshold group received RBC transfusions at an Hb above 7 g/dl, 
whereas this occurred in only 3% of the patients in the high threshold group. It was also more 
common for a patient in the high threshold group not to be transfused, in spite of their Hb 
being below the threshold (22% vs. 9% in the low threshold group). Consequently, the 
clinicians modified the protocol and made the differences smaller between the groups. 
However, the per-protocol analysis, which excluded patients who were transfused above their 
Hb threshold or not transfused below their threshold, showed a RR of 90-day mortality of 
0.92 (CI 0.77–1.09) when adjusted for the stratification variables. 
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If there is no benefit, in terms of either reduced mortality or morbidity, to RBC transfusion at 
a higher Hb level, it is probably best to choose the lowest safe threshold. This involves 
reduced costs and fewer risks to patients. Many other trials performed in different settings 
have come to similar conclusions. In the TRICC trial, Hebert and colleagues randomised 838 
critically ill patients to thresholds of 7.0 or 10.0 g/dl. There was no difference in 30-day 
mortality, but significantly more acute myocardial infarction (AMI) in the liberal group 
(0.7% in the restrictive and 1.2% in the liberal, p = 0.02) (23). In the FOCUS trial, patients > 
50 years old with a history of cardiovascular disease and Hb < 10 g/dl after hip fracture repair 
were randomised to thresholds of 8.0 or 10.0 g/dl. The primary outcome was a composite 
variable of death or inability to walk across a room without human assistance at 60 days. 
There was no statistically significant difference in the primary outcome or in the rate of AMI 
between the two groups (67). In a trial of 921 patients with acute gastrointestinal bleeding 
who were randomised to an Hb threshold of 7.0 or 9.0 g/dl, there was an HR for death at 45 
days of 0.55(CI 0.33–0.92) in the restrictive group. There were significantly more bleeding 
episodes in the liberal group (16% vs. 10%) (68). Following these trials, 7g/dl has been 
implemented in the NIH guidelines as the optimal Hb threshold in non-bleeding patients (69). 
However, there may be objections to this interpretation of the study results. The risk of a type 
II error was 20%. This is level of uncertainty usually accepted in clinical trials, although it 
could be argued that it ought to be lower (70). It is a weakness that we did not systematically 
evaluate for the clinically relevant signs and symptoms of myocardial ischemia. 
Consequently, we may have missed an increased incidence of AMI. A meta-analysis of trials 
comparing restrictive and liberal transfusion triggers in patients with acute and chronic 
cardiovascular disease showed no increase in mortality, but a risk ratio of 1.78(CI 1.18–2.70) 
for acute coronary syndrome in the restrictive group. The authors suggest that a transfusion 
trigger of 8 g/dl be used in patients with cardiovascular disease (71). The main objection to 
the study design, however, has been that administering RBCs in accordance with set 
transfusion triggers is not physiological. The main reason for administering RBCs to septic 
patients ought to be to increase oxygen uptake in the cells. It would then be more reasonable 
to administer RBCs to patients who had inadequate oxygen supply, displayed as low ScvO2 
or high blood lactate. However, there was no mortality benefit from RBC transfusion in 
response to low ScvO2 in the context of three large EGDT trials (44, 46, 72). A common 
problem with intensive care RCTs is patient selection. The population included is often 
highly selective and not representative of the entire ICU population. In the TRISS trial, 
however, there were few exclusion criteria. Other strengths of the trial are its size, the clear 
separation in Hb levels between the groups, the robust outcome variable (90-day mortality) 
and the fact that the study protocol reflects clinical practice in the ICU.  
 
6.2  THE ASSOCIATION BETWEEN FLUID BALANCE AND MORTALITY 
In Study II, we evaluated the 977 patients who had consented to our use of the full data set 
from Study I. There were 51 patients who died, 73 who were discharged and 7 had missing 
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fluid data. There were thus 841 surviving patients with ICU stays of at least three days and 
complete fluid data. The median cumulative fluid balance after three days was 2 480 ml (IQR 
47 - 5 045). The 90-day mortality was 52%. In the univariable Cox regression we found that 
age, presence of haematological malignancy, site (sites with < 10 patients were grouped 
together), chronic cardiovascular or lung disease, source of infection, baseline SOFA score, 
highest plasma lactate in the 24 hrs before randomisation and chronic RRT before 
randomisation were associated with mortality (p < 0.1). After adjustment for these variables 
in the multivariable analyses, no statistically significant association could be found between 
fluid balance and mortality (p = 0.37), which is illustrated in a survival plot (Fig. 12). When 
comparing a cumulative fluid balance after three days of > 75 ml/kg with a negative fluid 
balance, the hazard ratio (HR) was 1.3 (CI 0.97–1.75).  
 
  Fig. 12. Multivariable Cox regression survival plot for groups of 
cumulative fluid balance. The difference in mortality was not 
statistically significant, P = 0.37. 
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There are several cohort studies demonstrating an association between fluid balance and 
mortality (31-33, 73). The study populations, study size, covariates used for adjustment, 
cumulative fluid balance and ROB are illustrated in Table 2. 
Study  Patient 
group 
Patients 
n 
Measurement of association Cumulative fluid balance Risk of bias 
Boyd 
2011 
Septic 
shock 
778 HR for 28 d mortality 0.47(CI 
0.29–0.72) lowest compared 
to highest fluid balance group. 
Adjusted for age, APACHE 
II, dose of norepinephrine. 
Mean cumulative fluid 
balance day 4; 11 l. 
Post hoc analyses, potential 
selection bias with low 
screening/inclusion rate.  
Vincent 
2006 
 
 
 
Sepsis, 
15% 
septic 
shock 
1177 OR for ICU mortality 1.1/litre 
increase in cumulative fluid 
balance (CI 1.0–1.1). Adjusted 
for SOFA and SAPS II. 
 Mean cumulative fluid 
balance day 3;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
1.8 l. 
Few patients in septic shock. 
Mean fluid balance was
analysed as a continuous 
variable, which assumes a 
linear relationship between 
cumulative fluid balance and 
ln odds for mortality. 
Micek 
2013 
Septic 
shock 
325 OR for hospital mortality 
1.66(CI 1.39–1.98) for highest 
fluid balance quartile day 8 
compared to lowest. Adjusted 
for APACHE II, age, LVEF, 
vaso/inopressors, 
inappropriate antibiotics. 
Median cumulative fluid 
balance day 24 hours non-
survivors 4.4 l survivors 3.0 l. 
Retrospective, single centre 
study. Age analysed as 
continuous variable. 
Sadaka 
2014 
Septic 
shock 
350 HR for hospital mortality 
1.620 (95% CI, 1.197–2.043) 
highest 24-hour fluid balance 
compared to lowest. 
Categorised variables, Cox 
regression. Adjusted for age 
and SOFA score. 
Mean cumulative fluid 
balance 24 hours 6.5 l. 
Retrospective, single centre 
study. 
 
 
It is difficult to compare the results from the cohort studies. They differ in terms of study 
population, disease severity, amounts of fluids and statistical methods. If few variables are 
used for adjustment, the risk of residual confounding is larger. One objection to the statistics 
used above (73) is that if fluid balance is analysed as a continuous variable; it is assumed that 
the relationship between fluid balance and OR for mortality is linear. From a physiological 
point of view, it is reasonable to believe that the relationship between fluid balance and 
mortality is U-shaped. It is probably harmful to receive both too little and too much fluids. 
Furthermore, it is unlikely that every increase in fluid balance is associated equally with 
Table 2. Associations between fluid balance and mortality in earlier cohort studies 
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mortality. Another difference is that we analysed the fluid balance/patient weight. This 
should more adequately reflect the individual burden of fluid overload and thus the impact on 
mortality. One possible explanation why we did not demonstrate an association could be that 
the cumulative fluid balance in our cohort was relatively low. Fluid overload is perhaps only 
harmful above a certain level. 
Our results are consistent with those of some previous studies. In a small observational study 
of 164 patients in septic shock, mortality was lower if the patients had received > 7.5 l of 
resuscitation fluids over three days (74). A large RCT comparing liberal and conservative 
fluid management in patients with acute lung injury showed a shorter time on a ventilator in 
the conservative group, but no difference in mortality (40). 
The sample size of the study was too small to be able to exclude an association between fluid 
balance and mortality. The study had 60% power (post hoc calculation) to detect the crude 
difference in mortality of 8% between the two groups with the lowest fluid balance and the 
two groups with highest fluid balance.  
Another important objection is the cohort study design. It is uncertain whether a positive fluid 
balance increases mortality or is simply a marker of illness severity. All we can discuss with a 
study like this is associations. Even though we adjusted for many possible confounders, we 
cannot exclude residual confounding. To answer the question of whether fluids increase 
mortality in septic patients, we would need an RCT in which patients were randomised to 
either a restrictive or a liberal fluid protocol.  
6.3  PROTOCOLISED HAEMODYNAMIC MANAGEMENT IN CRITICALLY ILL 
PATIENTS  
We included 11 trials in Study III (Table 3) (43-46, 58, 75-80) . We decided to disregard 
blinding because no trial was blinded to the personnel providing the treatment. All the 
included studies had a low ROB in the domain of blinding of outcome assessment as they 
evaluated mortality. There were 6 trials with a low ROB (Fig. 13). These trials involved 
3 323 patients. The OR for mortality in the group with protocolised haemodynamic 
management was 0.94 (CI 0.73–1.22) (Fig, 14). 
  
Table 3. Description of trials included in the meta-analysis 
Values are presented as mean +/- standard deviation or as median (interquartile range). Abbreviations: APACHE = Acute 
Physiology and Chronic Health Evaluation, ABSI = abbreviated burn severity index, CI = cardiac index, CVP = central 
venous pressure, DO2I = oxygen delivery indexed to body surface,  EVLWI= extra vascular lung water index, FTc = flow 
time corrected , ITBVI = intra thoracic blood volume index, MAP = mean arterial pressure, PAC = pulmonary artery 
catheter, PAOP = pulmonary artery occlusion pressure, PLR = passive leg raising, ScvO2= central venous oxygenation, 
SOFA = Sequential Organ Failure Assessment, SVI = stroke volume index, UOP = urinary output 
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Author and 
year 
Location Population Type of 
monitoring 
Haemodynamic 
protocol 
Type of control 
protocol 
No. of 
patients 
Outcome 
Kuan 
2015 
 
Singapore Severe 
sepsis/septic 
shock patients 
Bioreactance Fluid bolus if PLR gave 
>10% increase in SVI 
MAP, usual care by 
clinician 
122 28-day 
mortality 
Holm 
2004 
 
Germany Burn unit 
patients 
Transpulmonary 
thermodilution 
Fluid boluses if 
ITBVI≤800 ml/m2 or 
CI<3.5 l/minxm2. 
Limited fluids if 
EVLWI>10 ml/kg 
Treatment according 
to Baxter formula 
50 Hospital 
mortality 
(secondary 
outcome) 
Pearse 
2005 
 
Great 
Britain 
ICU high risk 
surgical 
patients 
Lithium indicator 
dilution 
Fluid bolus to increase 
SVI>10%, Dopexamine 
to increase Do2I≥600 
ml/minxm2 
MAP and CVP 122 60-day 
mortality 
Chytra 
2007 
Czech 
Republic 
ICU trauma 
patients 
Oesophageal 
Doppler 
250 ml colloid bolus if 
FTc<0.35 s until SV 
increased<10% 
MAP and CVP 162 Hospital 
mortality 
(secondary 
outcome) 
Jones 
2010 
 
USA Septic shock 
patients 
ScvO2 Crystalloid boluses to 
achieve CVP>8 mmHg 
and MAP>65 mmHg. 
RBC transfusion or 
dobutamine to achieve 
ScvO2≥70% 
Lactate clearance 300 Hospital 
mortality 
Rivers 
2001 
 
USA 
 
Septic shock 
patients 
 
ScvO2 Crystalloid boluses to 
achieve CVP>8 mmHg 
RBC transfusion or 
dobutamine to achieve 
ScvO2≥70% 
MAP and CVP 
 
 
267 
Hospital 
mortality 
Zhang 
2015 
 
China Septic shock 
and/or ARDS 
patients 
Transpulmonary 
thermodilution 
Colloid boluses to 
achieve ITBVI≥850 
ml/min/m2 
MAP and CVP 350 28-day 
mortality 
Yealy 
2014 
 
USA 
 
Septic shock 
patients 
ScvO2 Crystalloid boluses to 
achieve CVP>8 mmHg. 
RBC transfusion or 
dobutamine to achieve 
ScvO2≥70% 
Heart rate/systolic 
blood pressure or 
usual care  
 
1 341 
Hospital 
mortality 
at 60 days 
Wheeler 
2006 
 
USA ARDS patients PAC Fluid bolus if 
MAP<60mmHg and 
UOP<0.5 ml/kg/h or 
CI<2.5L/ minxm2 and 
PAOP<18mmHg liberal, 
conservative 12 mmHg 
Fluid bolus if 
MAP<60mmHg and 
UOP<0.5 ml/kg/h or 
mottling and CVP<8 
mmHg conservative, 
14 mmHg liberal 
1 001 60-day 
mortality 
Peake 
2014 
 
Australia & 
New 
Zealand 
Septic shock 
patients 
 
ScvO2 
Crystalloid boluses to 
achieve CVP>8 mmHg. 
RBC transfusion or 
dobutamine to achieve 
ScvO2≥70% 
 
Usual care 
1 600  
90-day 
mortality 
Mouncey 
2015 
 
UK Septic shock 
patients 
ScvO2  Crystalloid boluses to 
achieve CVP>8 mmHg. 
RBC transfusion or 
dobutamine to achieve 
ScvO2≥70% 
Usual care  1 260 28-day 
mortality 
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Fig. 13. Assessment of validity of included studies according to the Cochrane Collaborative 
Tool for Risk of Bias Assessment. + = low risk of bias, - = high risk of bias, ? = unclear risk of 
bias. 
 
Fig. 14. Meta-analysis of effectiveness of hemodynamic monitoring combined with protocolised 
interventions to reduce mortality, low risk of bias trials. Weight is the relative contribution of 
each study to the overall treatment effect (odds ratio and 95% confidence interval) on a log scale 
assuming Mantel-Haenszel random effects model. 
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The trial sequential analysis showed that the estimated number of patients needed in order to 
exclude a positive effect with 80% power (the calculated IS) was 17 532 patients. We are 
therefore not able to exclude an effect on mortality using this meta-analysis. However, if the 
use of protocolised haemodynamic interventions does reduce mortality, the effect is likely to 
be small. Our results are in line with the results from a meta-analysis of EGDT trials, which 
did not show any reduction in mortality by using the EGDT protocol (81). Our results differ 
from an older meta-analysis performed before the new EGDT trials (82). 
Haemodynamic management has been a cornerstone of intensive care ever since the 
development of the flow-directed PAC in 1970. Why have we not been able to successfully 
prove that the treatment we deliver is beneficial to patients? A meta-analysis of well-
performed RCTs is supposed to provide the highest level of evidence. Nevertheless, if the 
quality of the included trials is low or the heterogeneity is large, the conclusions are 
uncertain. In order to evaluate the effect of protocolised haemodynamic management, the 
protocol must have a meaningful treatment goal, measurements must be correct, compliance 
with the protocol must be satisfactory and the control group must be treated using standard 
care. One problem with many trials is that they evaluate the effect of CVP-guided fluid 
therapy. CVP does not reflect fluid responsiveness (83). Neither do other static measures 
reflect fluid responsiveness. We only found three trials that evaluated the dynamic response 
to fluid (58, 76, 77). Kuan et al. performed a small trial without the intention of studying the 
effect on mortality. The other two were excluded from the analysis due to risk of bias. An 
inherent problem with haemodynamic trials is that it is impossible to blind the clinicians. 
Consequently, there is a substantial risk that the content of the protocol affects the treatment 
of the control group. This will reduce the effect of the investigated protocol. Critically ill 
patients are not a well-defined homogeneous group. It is hard to create a protocol that would 
suit every patient. It is possible that only the most severely ill patients really benefit from a 
structured approach and that their outcomes are drowned out by the information from the 
others. It might also be the case that a clinical judgment based on several signs indicating 
impaired perfusion (cold, mottled skin, high pulse rate, low blood pressure, low urinary 
output, high lactate) is better than a protocol based on one CO measurement. In conclusion, 
the optimal haemodynamic trial remains to be performed. It should be a trial with a dynamic 
measurement for evaluating fluid responsiveness, a reliable, safe haemodynamic 
measurement technique, a simple protocol that is acceptable to all clinicians and suitable for 
all patients and the trial size should be large enough to detect a clinically important difference 
in mortality. 
6.4  ASSESSING FLUID RESPONSIVENESS IN SEPTIC PATIENTS USING A 
PLR TEST 
Study IV was interrupted prematurely after the inclusion of 34/120 patients due to low 
weight gain in the control group. The power calculation was performed with the expectation 
of a weight gain of 8% of body weight in the controls and a reduction to a weight gain of 5% 
of body weight in the PLR group. In an interim analysis, we found that the mean weight gain 
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after three full ICU days was 0.6 (+/- 3.2) kg in the PLR group and 1.3 (+/- 3.9) kg in the 
control group (p = 0.59). The median amount of resuscitation fluid was 2 103 (IQR 1283 - 
2 645) ml in the PLR group and 2 408 (IQR 954 - 5 045) ml in the control group, (p = 0.38). 
The median total amount of fluid was 10 646 (7 851 - 12 092) ml in the PLR group and 
10 526 (6 158 - 12 902) ml in the control group (p = 0.67). Mean fluid balance was 1 566 (+/- 
3 725) ml in the PLR group and 2 669(+/- 2 675) ml in the control group (p = 0.33). We 
interrupted the trial because the small difference in weight gain was not judged to be of 
clinical importance.  
One possible reason for the low weight gain in the control group might be that the clinicians 
changed their pattern of fluid prescription during the study period. Maybe performing the 
study has made the physicians prescribe less fluid also in the control group. As the three large 
trials that tested the EGDT found that it did not reduce mortality, liberal fluid administration 
in septic patients has been called into question in the ICU community. This may have 
influenced the physicians’ behaviour. 
The study suffered from a low inclusion rate. Patients had to be included within 12 hours of 
the onset of septic shock. On-call clinicians might not have had time to include patient during 
the night as obtaining informed consent from relatives and initiating the PiCCO monitoring 
are time-consuming. If a patient was not included during the night, it was often too late to do 
so in the morning. Another PLR trial had similar problems with low inclusion rate (56). Sixty 
patients were included over 6 years. The main reason for not including eligible patients was 
time constraints for the physician. The CO monitoring ought to be non-invasive in order to 
make a PLR protocol more feasible. This would involve fewer risks to patients and less extra 
work for the attending physician. In a pilot trial, Chen and colleagues combined a PLR test 
with transoesophageal Doppler in intubated patients and transthoracic Doppler in non-
intubated patients (59). They managed to include 82 patients in one year (medical ICU in a 
hospital with 1 250 beds). They also included a component of de-resuscitation with active 
fluid restriction and elimination in patients who were not fluid responsive. This is interesting 
because resuscitation fluids were, at least in our study, only a minor (1/4–1/5) part of the total 
amount of fluid administered. If fluid administration is to be reduced, it is probably important 
to reduce the administration of maintenance fluids and fluids for the administration of drugs, 
as well as resuscitation fluids. 
The PLR test has been implemented in the emergency department with CO measured by 
bioimpedance (58). However, this measurement method has proven unreliable in validation 
studies (84). There were methodological weaknesses in our measurements too. According to 
the manufacturer, the accuracy of the bed scale was +/- 0.5 kg. In the clinical situation, an 
extra pillow or blanket might be left in the bed during the weighing procedure. There is 
therefore uncertainty regarding the point estimate of the outcome. The TPTD/pulse contour-
derived measurements of SVI are also inexact. Many studies have found a clinically 
acceptable agreement between TPTD and PAC-derived thermodilution (85) using the 
proposed percentage error ≤ 30%. This is based on the assumption that a < 20% error for each 
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type of measurement is acceptable when estimating the CI (86). However, in a study 
comparing PAC to PiCCO in patients during off-pump cardiac surgery, the bias and limit of 
agreement between PAC derived CI and pulse contour CI was -0.07 +/- 0.92 l/min/m2, with 
a percentage error of +/- 33.5%. This was when the measurements were performed before 
calibration of the pulse contour CI. The authors conclude that safe use of the pulse contour CI 
requires that calibration be performed during surgery (87). It can be questioned whether it is 
possible to use a cut-off of 10% increase in SVI to decide on fluid administration after a PLR 
test when the precision of the PiCCO measurements is this low (88). However, the latest 
recommendations for the cut-off for fluid responsiveness are ≥ 10 +/- 2% increase in CO (57). 
We were able to implement the protocol that prescribed a PLR test before every decision 
concerning the administration of resuscitation fluids, but the recruitment rate was low. We 
terminated the trial early as the weight gain was unexpectedly low in the control group. The 
protocol would have been more effective in a setting with a more liberal fluid administration. 
It would probably be better to protocolise the control group in order to make sure that the 
PLR protocol does not influence treatment in the control group.  
6.5 TIMING OF ANTIBIOTICS IN A COHORT OF SEPTIC ICU PATIENTS 
There were 64/210 (30%) patients who received antibiotics within one hour of their arrival in 
the emergency department. Median time to antibiotics was 38 (IQR 23 - 51) minutes in the 
early group and 211 (IQR 124 - 417) minutes in the late group. There was a lower proportion 
of women in the early group (28%) than in the late group (47%) (p = 0.015). There were 
more patients with surgical sepsis in the late group (25%) than in the early group (8%) (p = 
0.004).The crude 90-day mortality was 28% in the early group and 31% in the late group (p = 
0.75). After adjustment for SAPS 3 score, gender and surgical sepsis, there was no 
statistically significant association between antibiotic therapy later than one hour after arrival 
in the emergency department and 90-day mortality (OR 1.5, 95% CI 0.77–3.1). There are 
limitations with this study. Our sample size was too small to exclude an association 
between timing of antibiotics and mortality. The results cannot be generalised to the entire 
ICU population because only patients who stayed > 4 days in the ICU were included. There 
is a risk of selection bias as there might be patients suffering from sepsis who were not 
diagnosed correctly in the electronic monitoring system. 
There are several studies supporting the importance of early empiric antibiotics (60, 89-93). 
Three of these are prospective studies (90, 92, 93). There are also some studies that do not 
show an association between timing of antibiotics and mortality (62, 94-98). Some of them 
are, however, small and too underpowered to show a difference in mortality (62, 95, 98). It is 
hard to compare results from cohort studies; populations and inclusion criteria vary and 
different definitions of the onset of sepsis are used. Even if there are attempts to control for 
confounding factors, there is always the risk of residual confounding.  
As described in a recent meta-analysis and guideline from the National Institute for Health 
and Care Excellence, the timing of antibiotics in septic shock has not been investigated in 
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randomised clinical trials. The quality of evidence for the timing of antibiotics is very low. 
There was a significant reduction in all-cause mortality if antibiotics were administered 
within three hours (OR 0.70, CI 0.57–0.86). The recommendation, however, is that broad 
spectrum antibiotics should be administered within one hour in patients with a high risk of 
death from sepsis. There was no evidence of a difference between a delay of one hour and a 
delay of three hours (antibiotics within one hour compared to later, OR 0.87, CI 0.81–0.94) 
and the recommendation is that patients without organ dysfunction receive antibiotics within 
three hours. The group judged that the possible benefit of early administration of antibiotics 
would outweigh the risk of increased cost and increased resistance to antibiotics that this 
recommendation might lead to (99). Despite the low level of evidence, there is enough 
evidence that the early administration of adequate antibiotics is so important for patients in 
septic shock that it could not be evaluated in a RCT without a risk of patients being harmed. 
An important development will be the identification of microorganisms at the bedside. New 
ways of identifying microorganisms through molecular techniques are being introduced, for 
example IRIDICA, MALDI-ToF and others (100). These methods may significantly reduce 
the time taken to select the correct antibiotics and reduce the risk that resistance develops.  
We found an unexpected gender difference in the timing of antibiotics. The SAPS 3 score 
was similar in men and women, thus the difference could not be explained by the men 
being more severely ill. This finding will need to be confirmed in a larger sample size, 
ideally among all septic patients in the emergency department. 
In Swedish society, men and women have had equal rights since 1919 when women’s 
suffrage was enacted. It is not obvious why women should receive antibiotics later than 
men. Many gender differences have been documented in previous studies. In a large 
Canadian study, more men (60%) than women (40%) were treated in intensive care, 
although about the same number of women as men were treated in hospitals. Women over 
the age of 50 were also less likely to receive invasive treatment in the ICU and were more 
likely to die after critical illness (101). In a large retrospective study of septic ICU patients 
in the US, Canada and Brazil, women were less likely to receive mechanical ventilation, 
more likely to receive a limitation in treatment and the hospital mortality was 35% for 
women, compared with 33% for men (p = 0.006) (102). In order to explore whether the 
threshold for ICU admission differed based on gender, two surveys containing patient cases 
in which the gender was changed but everything else was kept the same were distributed to 
Swedish clinicians. No difference was found in the rate of ICU admission between male 
and female cases in this survey (103). However, there was a low response rate and it is 
uncertain whether the responses are representative of the entire medical profession. In a 
large retrospective study based on the Swedish ICU registry from 2008–2012, 
encompassing 127 240 admissions, 43% were women and their SAPS 3 at admission was 
lower than that of the male patients. Male sex was associated with higher use of ICU 
resources (104). There are many studies indicating gender differences in the treatment of 
critically ill patients. In order to understand these differences, qualitative studies of the 
attitudes and behaviour of clinical staff and patients are needed. 
 
 34 
7 GENERAL DISCUSSION 
7.1 WEAKNESSES OF THE THEORY OF FLUID RESPONSIVENESS 
The conventional way of increasing CO by giving fluids is firmly established in clinical 
practice. However, there are objections to the basic assumptions. A patient whose CO does 
not increase in response to fluids should not receive more fluids. But saying that a patient is 
fluid responsive is not the same as saying that there is a need for fluids. A patient who is fluid 
responsive does not necessarily benefit from fluid bolus therapy. The perceived benefit of 
filling patients with fluids until the heart is working on the flat part of the Frank-Starling 
curve is that this is an easy way to increase CO. Over the years, many protocols have been 
published the basic premise of which is reaching this level. This premise has been called into 
question (12), especially lately, as the risks of fluid overload have been highlighted. In the 
PLR protocol tested in Study IV, we only used the PLR test following a clinical decision to 
administer fluids. We used a lack of fluid responsiveness as a reason not to give fluids instead 
of using a positive PLR test as a reason to give fluids. Even if the patients fulfilled the clinical 
criteria for a fluid bolus and were fluid responsive in a PLR test, it is not certain that the fluid 
bolus therapy would lead to clinically important benefits. 
The rationale behind increasing CO is to improve systemic oxygen delivery. However it is 
unclear whether improved systemic circulation leads to enhanced microcirculation (105). 
There are many things that we still do not know about microcirculation. It is possible to 
monitor the microcirculation under the tongue (106), but the device available is expensive 
and is only used for research purposes. The correlation between the circulation under the 
tongue and the intestinal circulation is not clear (107). It is also uncertain whether enhanced 
microcirculation leads to improved clinical outcomes. In a recent trial comparing a protocol 
based on correction of the microcirculation with a protocol based on systemic haemodynamic 
parameters, there was no difference in SOFA score between the two groups on day four 
(108). It is not yet possible to target microcirculation during resuscitation in clinical practice, 
but when striving to optimise the systemic circulation, one should keep in mind that the goal 
is optimised cellular oxygen delivery. It is possible that an increased CO is an irrelevant goal. 
7.2 DIFFICULTIES WITH CLINICAL TRIALS IN CRITICALLY ILL PATIENTS 
There is an ongoing debate in the ICU research environment about whether it is possible to 
perform a positive clinical trial in critically ill patients. Many recent large, well-performed 
trials have been neutral. There are many possible explanations for this; it may be that the 
treatment targets are incorrect. The statistical power is dependent on the baseline risk of 
death, the size and variability of treatment effect and the size of modifiable mortality in the 
study population (109). It is common to overestimate the mortality rate when calculating the 
sample size both because mortality rates in sepsis are reported to be declining (110) and as 
patients who are at imminent risk of death are commonly excluded from trials. Sepsis is a 
syndrome with many complex pathophysiological pathways. It is thus unlikely that one single 
intervention could influence all-cause mortality. There is a large heterogeneity in population 
baseline risk of death in sepsis trials, which will lead to a wide variability in the possible 
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benefit from the studied intervention. In a neutral trial, there is a risk that there might be a 
high-risk group that consistently benefitted if there is not perfect collinearity between 
treatment harm and effects. It is also possible to have a positive trial in which one group was 
actually harmed (111). There are exceptions from the experience of neutral clinical trials. The 
6S trial showed increased mortality in patients with severe sepsis randomised to hydroxyethyl 
starch compared to Ringer’s acetate (112). This trial has significantly reduced the use of 
hydroxyethyl starch in septic patients (51). Another example of a recent large RCT that 
changed treatment recommendations was the Sepsis Occurrence in Acutely Ill Patients 
(SOAP) II trial, which compared norepinephrine to dopamine in septic shock. There was no 
statistically significant difference in mortality, but there were twice as many arrhythmias in 
the dopamine group (113). Norepinephrine is now recommended as the first line drug in 
septic shock (47). 
Clinical researchers are looking at outcomes other than mortality, e.g. clinical composite end-
points, with mortality retained as a safety assessment (109). Another suggestion is presenting 
mortality stratified by quintiles of baseline risk of death (111). If we want to detect small 
differences in mortality, large trials are needed. Cluster-randomised trials have been 
suggested as a way of performing larger studies. Registry-based trials are another way of 
making large trials possible (114). Individual patient data meta–analyses have also been 
attempted, for example with the three large EGDT trials (clinicaltrials.org NCT02030158). 
The way forward is unclear; all of these methods will probably be tested in the quest to 
increase our knowledge and improve clinical practice and outcomes for septic patients. 
 
7.3 CLINICAL IMPLICATIONS 
It is safe to adopt a Hb threshold of 7 g/dl in septic ICU patients except in patients with pre-
existing cardiovascular disease for whom a transfusion threshold of 8 g/dl is suggested. This 
reduces the number of RBC transfusions and the risk of complications from transfusion.  
It is still unclear whether fluid overload increases mortality. According to the Centre for 
Evidence Based Medicine scale (115), the level of evidence available is 2b, with this being 
individual cohort studies suggesting possible harm from fluid overload. While we wait for the 
results of RCTs, fluids should be regarded as drugs. Accordingly, fluids should not be 
prescribed without a clear indication and the intended effect should be weighed against 
possible side effects.  
There is no haemodynamic protocol that has been shown to consistently reduce mortality. As 
clinicians, we are left to support the circulation of our patients as best we can. One clinical 
recommendation concerning the administration of fluids in septic shock could be to monitor 
cardiac output in patients who cannot be stabilised by initial resuscitation. The response to 
fluids may be assessed subsequently using a PLR test, after which fluid administration may 
be reduced for those patients who are fluid responsive. This is in line with the latest European 
Society of Intensive Care Medicine task force recommendations: 
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‘We recommend measurements of cardiac output and stroke volume to evaluate the 
response to fluids or inotropes in patients that are not responding to initial therapy. 
Level 1; QoE [quality of evidence] low (C) […] We recommend using dynamic over 
static variables to predict fluid responsiveness, when applicable. Level 1; QoE 
moderate (B). When the decision for fluid administration is made we recommend to 
perform a fluid challenge, unless in cases of obvious hypovolemia (such as overt 
bleeding in a ruptured aneurysm). Level 1; QoE low (C). We recommend that even in 
the context of fluid responsive patients, fluid management should be titrated 
carefully, especially in the presence of elevated intravascular filling pressures or 
extravascular lung water. Ungraded best practice.’(12). 
The most up-to-date recommendation concerning the timing of antibiotics in septic patients 
is that published by the National Institute for Health and Care Excellence in 2016. This 
recommendation is that broad spectrum antibiotics should be administered within one hour in 
patients with high risk of death from sepsis. Patients without organ dysfunction should 
receive antibiotics within three hours. The group considered the overprescription of broad 
spectrum antibiotics that this recommendation might bring about, and judged that the possible 
benefit of early administration of antibiotics would outweigh the risk of increased cost and 
increased resistance to antibiotics (99).  
 
7.4 FUTURE RESEARCH 
7.4.1 Haemodynamic effects of fluid therapy 
There are basic questions concerning fluid therapy in septic patients that need to be answered. 
Clinicians administer fluids in order to correct hypotension, tachycardia, oliguria and poor 
tissue perfusion. It is unknown to what extent these goals are fulfilled by the administration of 
fluids. The expected and actual effects of fluid administration in septic patients need to be 
studied in order to help clinicians make better-informed decisions about how to administer 
fluids. 
In the ER and the operating theatre fluids are often warmed to body temperature when large 
volumes are administered. In the ICU, fluids are usually administered at room temperature. 
Because room temperature fluids are colder than the patient, this may cause sympathetic 
mediated arterial vasoconstriction and a consequent rise in blood pressure, but diminished 
peripheral perfusion (116). It would be interesting to know if parts of the haemodynamic response 
to fluids could be due to cooling.  
7.4.2 Alternatives to current fluid administration in septic shock 
 In sepsis, vasodilatation is the main reason for hypotension. A rational approach would be to 
administer vasopressors at an early stage, provided no fluid has actually been lost. One 
important question is how much fluid should be administered before the initiation of 
vasopressors. The SSC guidelines recommend at least 30 ml/kg over the first three hours, but 
there is no direct evidence to support this recommendation (47). One obstacle to early 
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administration of vasopressors is that it is a long-standing practice that norepinephrine has to 
be administered through a central line, which (in Sweden) is not usually available until the 
patient is admitted to the ICU. A peripheral line is shorter (usually 2.5–4 cm) and the risk of 
displacement is higher than with a central line (15–25 cm). A displaced line could lead to 
extravasation of norepinephrine, which might lead to necrosis. A recent trial showed that 
norepinephrine could be administered safely via a peripheral line (117). However, this was 
performed using a very rigorous protocol in an ICU. The safe use of peripheral 
norepinephrine in the emergency department and the operating theatre needs to be studied, as 
does the minimum amount of fluid that should be administered before the initiation of 
norepinephrine. 
Studying the impact of restrictive as opposed to standard fluid therapy on mortality, 
maintenance fluids included, is a high priority. 
7.4.3 Evaluation of individualised goals for resuscitation 
In the future, when there is a non-invasive CO monitoring device that is both accurate and 
precise, there may be time to perform a PLR trial with a haemodynamic protocol similar to 
ours. It could then be argued that it is possible to use delayed informed consent as there 
would be minimal risk to the patients. The inclusion rate might then be improved, making a 
large-scale trial feasible. It is important to continue studying haemodynamic optimisation. As 
expressed in the conclusion of a recent Cochrane review of the use of vasopressors in septic 
shock:  
‘In the light of current evidence, additional well-designed studies with individual goals 
of resuscitation including clinical parameters of end-organ perfusion and appropriate 
patient-relevant outcome end points are urgently needed’ (118).  
Different resuscitation targets have been proposed. The difference between central venous 
and arterial PCO2 (∆PavCO2) increases when microcirculation is impaired. It has been 
suggested that a combination of ScvO2 and ∆PavCO2 could be used to detect patients with 
impaired microcirculation despite normalised ScvO2 (100). Another possible haemodynamic 
goal could be to keep the CVP low instead of high. The organ blood flow is determined by 
the difference between MAP and CVP and the resistance to flow. A high CVP has been 
shown to be associated with acute kidney injury (119). An algorithm to reduce CVP would 
perhaps increase renal blood flow and decrease the incidence of acute kidney injury. 
7.4.4 Reducing leakage from blood vessels by protecting the glycocalyx 
The role of the glycocalyx is described in a modified Starling model (120). It would be 
interesting to find a way to reduce the endothelial damage in sepsis. Experiments have been 
performed in which albumin protects the glycocalyx (121) . Early administration of albumin 
to protect the glycocalyx has not been tested in patients. The challenge lies in administering 
the albumin before the glycocalyx is damaged as the autonomous adrenergic reaction to low 
blood pressure damages the endothelium at an early stage. It would be interesting to study 
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whether administering albumin in the ambulance to patients with suspected infection and 
hypotension protects the glyocalyx and reduces leakage from vessels.  
7.4.5 Gender differences in the treatment of septic patients 
Female gender was associated with later administration of antibiotics. A prospective study 
that includes all patients with sepsis should be performed in the emergency department 
setting. If the difference in timing of antibiotics between men and women persists, the 
reasons for this should be investigated using qualitative studies of attitudes among patients, 
relatives and healthcare personnel. Possible explanations for a gender difference in the timing 
of antibiotics are that women present symptoms differently when they have sepsis and organ 
dysfunction. Women are perhaps less likely to complain. Another possibility is that 
healthcare personnel act differently when caring for men than when caring for women.  
7.5 REFLECTIONS CONCERNING LEARNING OUTCOMES 
There are many things that have been important to my development as a researcher. I will 
describe some of the key elements. A fellow doctoral student and I have held monthly journal 
clubs in order to learn to critically appraise literature. I have attended research courses where 
I have learned about legislation, ethics and statistics. I have also learned that in research, 
things do not always turn out the way you expected. I started conducting a registry based 
study because I thought that the data-gathering phase would be short. It turned out to be 
impossible to obtain the data I needed. Instead of being a short cut to learning about analyses 
and writing, it was a circuitous route. Through research collaboration and visits to 
Copenhagen and Melbourne, I have had the opportunity to learn from clinical researchers 
how to plan and run clinical ICU trials. I have learned that high quality ICU research is best 
done in collaboration between ICUs. 
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8 CONCLUSION 
The scientific support for how clinical fluid management in patients with septic shock should 
be performed is poor. More research is needed in order to show whether reducing fluid 
overload can decrease mortality. In the meantime, fluids should be treated as drugs and 
should not be prescribed without a clear indication. The intended effect should be weighed 
against possible side effects. 
 It is safe to adopt a Hb threshold of 7 g/dl in septic ICU patients except in patients 
with pre-existing cardiovascular disease for whom a transfusion threshold of 8 g/dl is 
suggested. 
  It is uncertain whether fluid overload is associated with mortality at median 
cumulative fluid balance of 2.5 l on day three.  
 It has not been proven that protocolised haemodynamic management improves 
outcome. 
 It was possible to use the protocol based on a PLR test, but the recruitment rate was 
low. The weight gain was low in both the PLR and the control groups. 
 Female patients and patients with surgical sepsis were overrepresented in the group 
that received antibiotics after more than one hour in the emergency room. We could 
neither confirm nor exclude a survival benefit from early administration of antibiotics. 
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9 SUMMARY OF THESIS IN SWEDISH 
9.1 BEHANDLING AV PATIENTER MED BLODFÖRGIFTNING-VÄTSKA, BLOD 
OCH TID TILL ANTIBIOTIKA 
Bakgrund: Blodförgiftning, eller sepsis, är när en infektion leder till en okontrollerad 
immunologisk reaktion som i sin tur leder till skada på livsviktiga organ. Vätska borde, 
utifrån ett fysiologiskt resonemang, ges till patienter med sviktande cirkulation för att öka 
hjärtminutvolymen och därmed leveransen av syrgas till kroppens vävnader. Det är dock 
endast hälften av kritiskt sjuka patienter som ökar sin hjärtminutvolym efter tillförsel av 
vätska. Läkare förskriver vätska för att korrigera lågt blodtryck, hög puls, låg urinproduktion 
och dålig perifer genomblödning. Dessa parametrar kan inte förutsäga om en patient kommer 
att svara på vätska med en ökad hjärtminutvolym. Internationella riktlinjer säger att patienter 
med blodförgiftning och sviktande cirkulation ska få minst 30 ml vätska/kg kroppsvikt. Det 
finns inga riktlinjer för när vätsketillförseln bör minska. Detta har lett till övervätskning av 
patienter med blodförgiftning. Det finns många observationsstudier som visat på en 
association mellan övervätskning och dödlighet. Svagheten med dessa studier är att de inte 
kan berätta om vätskan är orsaken till den ökade dödligheten, eller bara ett tecken på att de 
patienter som fick större mängd vätska var sjukare. Patienter med blodförgiftning och 
blodbrist får ibland röda blodkroppar för att säkerställa att kroppen får tillräckligt med syre. 
Det finns risker med att ge röda blodkroppar, som övervätskning, immunologiska reaktioner 
och infektioner. Trots tidigare studier är det osäkert vid vilken Hb-gräns som patienter med 
blodförgiftning ska få röda blodkroppar. Det finns studier som visat ett starkt samband mellan 
tid till antibiotika vid blodförgiftning med sviktande cirkulation. Internationella riktlinjer 
rekommenderar att antibiotika ska ges inom en timme från att cirkulationssvikt 
diagnosticerats. 
Studie I var en klinisk studie där patienterna lottades till Hb-gräns för blodtransfusion på 70 
eller 90 g/l. De som hade Hb 70 g/l som gräns fick påtagligt mindre blod. Det var ingen 
skillnad i dödlighet efter nittio dagar eller i antal hjärtkomplikationer. Studien visar att det är 
säkert att använda sig av 70 g/l som Hb gräns vid blodförgiftning med cirkulationspåverkan, 
vilket stämmer överens med studier som undersökt andra patientgrupper.  En senare 
metaanalys har visat att patienter med kronisk hjärtsjukdom bör ha Hb 80 g/l som gräns för 
transfusion. 
Studie II undersökte sambandet mellan vätskebalans efter tre dagar på IVA och dödlighet 
efter 90 dagar i studie I. Medianvärdet för vätskebalansen efter tre dagar var +2,5 l. Det fanns 
inget statistiskt säkerställt samband mellan vätskebalans och dödlighet efter korrigering för 
faktorer som kunde förväntas påverka både dödlighet och hur mycket vätska patienterna fick. 
Detta står i kontrast till vad som visats i många andra studier. Skillnaden skulle kunna bero på 
att våra patienter hade en lägre ackumulerad vätskebalans än vad patienter haft i tidigare 
studier, eller att övervätskning blir farligt först efter en viss mängd. Dock var patientantalet 
något för litet för att vi säkert skulle kunna utesluta att övervätskning på denna nivå var 
associerad med dödlighet. 
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Studie III var en metaanalys av studier som undersökt effekten på dödlighet av att använda 
ett hemodynamiskt schema hos kritiskt sjuka patienter. Vi använde protokollet i Cochranes 
handbok för systematisk genomgång av interventioner. Vi krävde att det hemodynamiska 
schemat skulle vara grundat på hjärtminutvolym, slagvolym, slagvolymsvariation, 
syrgasleverans, centralvenös syremättnad eller blandvenös syremättnad. Kontrollgruppen fick 
inte ha någon sådan mätning. Vi inkluderade elva studier. Av dessa var det bara sex som höll 
en kvalitet som levde upp till Cochranes krav på låg risk för systematiska fel. Det var ingen 
statistiskt säkerställd minskning av dödlighet i grupperna som behandlats enligt ett 
hemodynamiskt schema. Antalet patienter var dock för få för att vi skulle kunna utesluta att 
avsaknaden av en skillnad hade uppkommit av en slump. Dessutom är det avgörande att rätt 
mål tillämpas i ett hemodynamiskt schema. Bara en av de sex studierna använde ett 
dynamiskt mått på svar på vätska. Slutsatsen är att det finns för litet underlag för att uttala sig 
om huruvida ett hemodynamiskt schema kan påverka dödligheten.  
Studie IV var en klinisk studie där patienter på intensivvårdsavdelningen med 
blodförgiftning och cirkulationspåverkan lottades till ett hemodynamskt schema grundat på 
resultatet av ett benlyftstest eller vanlig behandling. Benlyft gjordes om läkaren, baserat på 
klinisk bedömning, trodde att patienten behövde vätska. Om slagvolymsindex ökade med 
10% eller mer vid benlyft tolkades detta som att patienten kunde svara på vätska och läkaren 
fick då ordinera önskad mängd vätska. Om slagvolymsindex ökade med <10% fick ingen 
vätska ges. Syftet var att se om användandet av detta hemodynamiska schema skulle leda till 
minskad viktuppgång. Vi hade planerat en studiestorlek på 120 patienter, baserat på en 
förväntad viktuppgång på 8% av kroppsvikten. Efter en interrimsanalys visade sig 
viktuppgången i kontrollgruppen vara betydligt lägre än beräknat. Vi valde att avsluta studien 
i förtid pga att vi bedömde att viktuppgången i kontrollgruppen var för liten för att vara av 
betydelse för patienterna. 
Studie V var en journalstudie av tid från ankomst till akuten till antibiotika och dödlighet 
efter nittio dagar hos patienter som vårdas för blodförgiftning på IVA. Trettio procent fick 
antibiotika inom en timme. Kvinnor fick antibiotika senare än män.  
Slutsats: Det finns bristande vetenskapligt stöd för hur vätskebehandling vid blodförgiftning 
ska göras. Det behövs kliniska studier som jämför restriktiv med liberal vätskebehandling för 
att se om dödligheten kan minska genom minskad övervätskning.  
Klinisk tillämpning: Vid blodförgiftning bör Hb 70 g/l användas som gräns för transfusion 
om patienterna inte har pågående hjärtinfarkt. Patienter med kronisk hjärtsjukdom bör dock 
ha Hb 80 g/l som gräns för transfusion. Vätska bör inte ges utan att den förväntade effekten 
vägs mot möjliga negativa effekter. Ett expertråd är att patienter som inte initialt stabiliseras 
av vätska bör övervakas med mätning av hjärtminutvolym. Då är det möjligt att med ett 
benlyftstest avgöra om patienten kommer att svara på vätska med ökad hjärtminutvolym.  
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